Enhanced early detection of diabetic kidney disease occurs with the integration of synergistic biomarkers and serum metabolites, leading to better outcomes.
The combined approach of using both biomarkers and serum metabolites shows significant potential for impacting disease progression.
Assessment through integration of various biomarkers indicates a more reliable identification of diabetic kidney disease at earlier stages.
This strategy supports the need for more comprehensive screening methods to identify diabetic kidney disease effectively.
Abstract
Integrating synergistic biomarkers with serum metabolomics enhances early detection of DKD, potentially improving outcomes by slowing disease progression in T2DM patients.